52
Participants
Start Date
June 20, 2018
Primary Completion Date
June 30, 2025
Study Completion Date
June 30, 2025
Virus Specific T-cell (VST) infusion
Patients will receive partially HLA-matched VSTs as a single infusion. Patients who have a partial response (\>1 log decrease in viral load without clearance) or no response and do not have treatment-related dose-limiting toxicities are eligible to receive up to 3 additional doses from day 30 after the initial infusion and at 2 weekly intervals thereafter. The viral load of the virus (or viruses) that patients are initially treated for are monitored by viral PCR.
Columbia University Medical Center, New York
Roswell Park Comprehensive Cancer Center, Buffalo
The Children's Hospital, Philadelphia
Children's National Medical Center, Washington D.C.
Virginia Commonwealth University, Richmond
Duke University Medical Center, Durham
Medical University of South Carolina, Charleston
Emory University/Children's Healthcare of Atlanta, Atlanta
St. Jude, Memphis
Riley Hospital for Children - Indiana University, Indianapolis
University of Michigan, Ann Arbor
Spectrum Health - Helen DeVos Children's Hospital, Grand Rapids
University of Minnesota, Minneapolis
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Washington University, St Louis
UT Southwestern Medical Center, Dallas
Children's Mercy, San Antonio
Methodist Healthcare System of San Antonio, San Antonio
Children's Hospital Colorado, Aurora
Phoenix Children's Hospital, Phoenix
University of California, Los Angeles, Los Angeles
City of Hope, Duarte
Children's Hospital Los Angeles, Los Angeles
UCSF Medical Center, San Francisco
Stanford Lucile Packard Children's Hospital, Palo Alto
Oregon Health & Science University, Portland
Fred Hutchinson Cancer Research Center/Seattle Chlindren's/University of Washington School of Medicine, Seattle
Yale, New Haven
Tufts Medical Center, Boston
Dana-Farber Cancer Institute/ Boston Children's Hospital, Boston
Pediatric Transplantation & Cellular Therapy Consortium
OTHER